Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis
ABSTRACT Prior pharmacokinetic (PK) analysis revealed that increased alpha‐1‐acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID‐19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib...
Saved in:
| Main Authors: | Medhat M. Said, Job R. Schippers, Leila Atmowihardjo, Yingxue Li, Mick S. van derPlas, Harm J. Bogaard, Lieuwe D. J. Bos, Ron A. A. Mathôt, Jurjan Aman, Eleonora L. Swart, Imke H. Bartelink |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-03-01
|
| Series: | CPT: Pharmacometrics & Systems Pharmacology |
| Online Access: | https://doi.org/10.1002/psp4.13299 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A rare adverse drug reaction of imatinib mesylate
by: Ramya Ravichandar, et al.
Published: (2019-01-01) -
Imatinib detection by memristive biosensors for therapeutic drug monitoring
by: Junrui Chen, et al.
Published: (2025-08-01) -
Therapeutic drug monitoring for imatinib: Current status and Indian experience
by: Brijesh Arora, et al.
Published: (2013-01-01) -
Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia.
by: Kibum Kim, et al.
Published: (2019-01-01) -
Immunobiological effects of tocilizumab across respiratory subphenotypes in COVID-19 ARDS
by: Emma Rademaker, et al.
Published: (2025-07-01)